P R O F E S S I O N A L P R A C T I C E M AT E R I A L S
NR 565 Advanced Pharmacology Final
Exam Questions & Answers 2026-2027
| Chamberlain Practice Exam |
Ultimate Review Guide (Rationales)
Verified Answers Exam Ready With Rationales
95 QUESTIONS
DOCUMENT OVERVIEW
This document provides 95 verified exam questions with correct answers and detailed rationales focused on
advanced pharmacology. It is suitable for comprehensive review and effective study for certification exams.
The in-depth explanations enhance understanding and retention of key pharmacological concepts, making
it an essential resource for students preparing for advanced practice nursing assessments.
CONTENTS
01 Diabetes Management Q1–Q16
02 Cardiovascular Considerations Q17–Q27
03 Thyroid Disorders Q28–Q42
04 Medication Contraindications Q43–Q56
05 Asthma and COPD Q57–Q71
06 Gastrointestinal Pharmacology Q72–Q85
07 Vaccination and Immunology Q86–Q95
E XA M Q U EST I O N S
Q1 QUESTION 1 OF 95
Page 1
,In which patient population is Metformin contraindicated in?
A. Diabetics with HA1c < 7.0%
B. Patients older than 50
C. Alcoholics
D. Women suffering from infertility
CORRECT ANSWER
C. Alcoholics
RATIONALE
Metformin is contraindicated in individuals with a history of alcoholism due to the increased risk of lactic acidosis, a potentially life-threatening condition
exacerbated by impaired hepatic function and alcohol-induced metabolic changes. This highlights the importance of assessing a patient's alcohol
consumption and liver function before initiating treatment with this medication.
Q2 QUESTION 2 OF 95
What lab value suggests metformin might be contraindicated?
A. eGFR <30
B. Crea 0.8
C. WBC 7.8
D. Bun 17
CORRECT ANSWER
A. eGFR <30
RATIONALE
An eGFR below 30 mL/min indicates significantly reduced renal function, increasing the risk of lactic acidosis when using metformin, which is contraindicated
in such cases. Monitoring renal function is critical to ensure safe medication management and prevent serious complications.
Q3 QUESTION 3 OF 95
Which of the following medications would be considered the first line of treatment for a newly diagnosed Diabetic patient with adequate renal
and hepatic function?
A: NovoLog Sliding Scale Insulin
B: Liraglutide (Victoza)
C: Oral Metformin
D: Glipizide
CORRECT ANSWER
C: Oral Metformin
RATIONALE
Metformin is the first-line pharmacotherapy for type 2 diabetes due to its ability to improve insulin sensitivity and reduce hepatic glucose production without
causing weight gain or hypoglycemia. Its efficacy, safety profile, and benefits on cardiovascular outcomes make it the cornerstone of diabetes management in
patients with normal renal and hepatic function.
Q4 QUESTION 4 OF 95
Of the following medications, which is most likely to cause hypoglycemia?
A. Metformin
Page 2
,B. Insulin
C. Incretin mimetics
D. Thiazolidinediones
CORRECT ANSWER
B. Insulin
RATIONALE
Insulin directly lowers blood glucose levels by facilitating cellular uptake of glucose, making it the most potent medication among the options for inducing
hypoglycemia, particularly if dosed in excess or without adequate carbohydrate intake. Other agents listed, such as metformin and thiazolidinediones,
primarily enhance insulin sensitivity and do not typically cause hypoglycemia on their own.
Q5 QUESTION 5 OF 95
A 45-year-old patient with a history of type 2 diabetes presents to the clinic for a follow-up appointment. The healthcare provider has prescribed
metformin as part of the treatment plan. Which of the following statements regarding metformin is correct?
A. Metformin primarily stimulates insulin production from the pancreas.
B. Metformin reduces glucose levels primarily by decreasing insulin resistance.
C. Metformin is associated with a risk of hypoglycemia.
D. Metformin improves insulin sensitivity and reduces hepatic glucose production.
CORRECT ANSWER
D. Metformin improves insulin sensitivity and reduces hepatic glucose production.
RATIONALE
Metformin enhances insulin sensitivity in peripheral tissues and decreases hepatic glucose output, which effectively lowers blood glucose levels without
increasing insulin secretion, thus minimizing the risk of hypoglycemia. This mechanism is central to its role in managing type 2 diabetes.
Q6 QUESTION 6 OF 95
In what part of the body are SGLT-2 (sodium-glucose cotransporter 2) inhibitors active?
A. Small intestine
B. Pancreas
C. Renal tubules
D. Stomach
CORRECT ANSWER
C. Renal tubules
RATIONALE
SGLT-2 inhibitors function by blocking the reabsorption of glucose in the renal tubules, leading to increased glucose excretion in the urine and improved
glycemic control. This mechanism highlights their role in managing conditions like type 2 diabetes by targeting renal glucose transport.
Q7 QUESTION 7 OF 95
The correct drug classification of Ciclesonide is
A. Methylazanthine
B. Inhaled Corticosteroid
Page 3
, C. Short-acting Beta Agonist
D. Leukotriene Receptor Antagonist
CORRECT ANSWER
B. Inhaled Corticosteroid
RATIONALE
Ciclesonide functions as an inhaled corticosteroid, which reduces inflammation in the airways and improves respiratory function in conditions like asthma
and COPD. This drug classification is characterized by its ability to modulate immune responses and decrease airway hyperreactivity.
Q8 QUESTION 8 OF 95
A patient presents with an A1C of 11.2%. Which medication should be considered at this time?
A. Insulin
B. Metformin
C. Glipizide
D. sitagliptin
CORRECT ANSWER
A. Insulin
RATIONALE
2% indicates poor glycemic control and may require prompt intervention to prevent complications; insulin provides rapid and effective glucose regulation in
such cases. Initiating insulin therapy allows for more precise management of hyperglycemia compared to oral agents, which may take longer to achieve
desired outcomes.
Q9 QUESTION 9 OF 95
In diabetes, older adults should maintain an A1C
A. less than 8%
B. less than 7%
C. less than or equal to 6.5%
D. less than 10%
CORRECT ANSWER
A. less than 8%
RATIONALE
Maintaining an A1C level of less than 8% in older adults with diabetes helps balance glycemic control while minimizing the risk of hypoglycemia and its
associated complications, considering their health status and potential comorbidities. This target recognizes the need for individualized treatment goals that
prioritize quality of life and functional status.
Q10 QUESTION 10 OF 95
How often should an A1C be drawn?
A. 18 months
B. q 3-6 months
Page 4